Dr. Ashok Srivastava

Dr. Ashok Srivastava |Clyto Access

Chief Executive Officer and Chief Medical Officer of ClinFomatrix Oncology and Chief Executive Officer of Cure Pharmaceuticals, Inc., USA.

Keynote Speaker
Organizing Committee Member

Expertise: Oncology/Hematology (Drug development)

Biography: Dr. Ashok Srivastava is Chief Executive Officer and Chief Medical Officer of ClinFomatrix Oncology and Chief Executive Officer of Cure Pharmaceuticals, Inc., USA.. He was also founder and Chief Medical Officer of Global Pharmatek clinical and drug safety Oncology, USA, and Chief Medical Officer of CareBeyond - A Radiation Cancer Center in USA. He has more than 17 years of experience in drug development , medical affairs and commercialization of cancer drugs including radiopharmaceutical and supportive care; Phase I – 4, and marketing commercialization of immuno-oncology, hematology, oncology and radio pharmacetuical drugs in USA , EU and Japan. He is leader in Cancer Drug Development Worldwide large Phase 2 and 3 clinical trials in many countries. He contributed to 21-INDs and 7-NDAs of Cancer Drugs and supportive care, acquisition /merger of pharma and drug for more than $300 million . He received his clinical, medical training & worked at renowned medical centers and pharmaceutical institutions worldwide; Walter Reed Army Institute of Research and Medical Center, Daiichi, Sumitomo, Pharmacia, Pfizer, Sopherion Oncology., Eisai Oncology, and Spectrum Pharmaceuticals. He received his Clinical, Medical & Business educations from All India Institute of Medical Sciences, New Delhi, India ; Academy of Medical Sciences, Czechoslovakia; School of Medicine Nagasaki University, Nagasaki, Japan, and Pharmaceutical Business at Rutgers University Business Management, New Jersey, USA. He played key role in dramatic expansion of oncology drug – developed cancer drugs- Sutent (Sunitinib), Evoxac (Cevimeline HCl), and liposomal doxorubicin (Myocet) in combination with Herceptin & Paclitaxel for HER2 positive metastatic breast cancer patients and latuda (Lurasidone) for schizophrenia . He is one of the inventors of Japanese encephalitis vaccine (IXIARO) . He has published more than 85 papers in National and International Journals, more than 120 abstracts, 3 book chapters and 2 patents. He is recipient of numerous National & International prestigious medical awards and recognitions from United Nations, Ministry of Health, Japan, and Department of Army, Walter Reed Army Medical Center and Walter Reed Army Institute of Research, Washington DC, USA. He served as medical advisor to Poniard Pharmaceutical for small cell lung cancer in USA, EU and India. He is member of numerous prestigious organizations; America’s Top Oncologist of the years 2007- 2011, Breast Cancer Foundation , Indian Society of Oncology, American Society of Clinical Oncology, American Society for Therapeutic Radiology & Oncology, American Association of Cancer Research, and International Society of Lung Cancer. Dr. Srivastava is a strategic medical advisor and Board Member to several pharma in USA for clinical, regulatory and supervises cancer drug development . Recently Dr. Srivastava was awarded membership of Japan External Trade Organization, USA. Dr. Srivastava is a Leader in Drug Safety, pharmacovigilance of hematology, Oncology drugs and built a global drug safety and pharmacovigilance companies in USA, and India. Dr. Srivastava was invited as an honorable speaker at drug safety & Pharmacovigilance congress in London, UK , China and India in Jan 2012, 2013 and 2017. Dr. Srivastava brought 2 cancer drugs & a vaccine in global market for approx 3 – 3.5 billion $ global sales. He serves as board of director s for oncology virtual pharma companies in USA .,

Related Conferences :